Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin


A total of 21 patients with advanced cancer were entered into a phase I study to determine the maximum tolerable dose (MTD) of liposome-encapsulated doxorubicin (LED) given weekly for 3 consecutive weeks at doses of 20, 30, or 37.5 mg/m2 per week. For a comparison of the pharmacokinetic behavior of LED with that of standard-formulation doxorubicin, 13… (More)
DOI: 10.1007/BF00685327


5 Figures and Tables